Clinical trials: Intravenous Administration
Left Ventricle Function
Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction
To explore if AZD1305 compromises left ventricular performance in patients with left ventricular dysfunction
- Trial name
- NCT00748982
- Testing
- AZD1305
- Where
- Sweden
- Volunteers
- 16 people
- Sponsor
- AstraZeneca
Pulmonary Hypertension
Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin
The purpose of this 8-week study is to compare the effects of switching from therapy with epoprostenol or Flolan to IV Remodulin.
- Trial name
- NCT00373360
- Testing
- treprostinil sodium
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- United Therapeutics
Graves Ophthalmopathy
A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease
The purpose of this study is to investigate the safety and tolerability of otelixizumab in patients with Graves' ophthalmopathy (thyroid eye disease).
- Trial name
- NCT01114503
- Testing
- Otelixizumab - low dose, Otelixizumab - medium low dose, Otelixizumab - medium high dose
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- GlaxoSmithKline
Pain
Effects of Intravenous GSK3858279 on a Battery of Evoked Pain Tests in Healthy Volunteers
This study will evaluate the mechanistic basis for the analgesic effects of GSK3858279 in humans by using a battery of experimental pain assessments in healthy participants.
- Trial name
- NCT04114656
- Testing
- GSK3858279
- Where
- Netherlands
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Anemia
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
This study will assess the efficacy and safety of intravenous (iv) Mircera given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv darbepoetin alfa.
- Trial name
- NCT00077766
- Testing
- Darbepoetin alfa, methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 48 sites in Australia, Austria and 10 more
- Volunteers
- 313 people
- Sponsor
- Hoffmann-La Roche
Healthy Volunteers, Rheumatoid Arthritis
A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)
The purpose of this study is to assess the safety and tolerability of CPTX2309 in healthy adult participants and adult participants with moderate to severe rheumatoid arthritis or systemic lupus erythematosus.
- Conditions
- Healthy Volunteers, Rheumatoid Arthritis, Systemic Lupus Erythematosus
- Trial name
- NCT06917742
- Testing
- CPTX2309
- Where
- 3 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Capstan Therapeutics
Osteoporosis in Post-menopausal Women, Osteoporosis
Intravenous Infusion of Human Mesenchymal Stem Cells (HMM910 ) in Postmenopausal Women With Osteoporosis at High Risk of Fracture
The primary objective of this study is to evaluate the safety and tolerability of human umbilical cord-derived mesenchymal stem cells for injection (HMM910 ) in postmenopausal women with osteoporosis who are at high risk of…
- Trial name
- NCT06949137
- Testing
- Human Umbilical Cord-derived Mesenchymal stem cell
- Where
- China
- Volunteers
- 9 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Chronic Inflammatory Demyelinating Polyneuropathy
A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC
This study will measure how adults with CIDP receiving IVIg treatment adjust to efgartigimod PH20 SC. The study duration for each participant will be approximately 17 to 19 weeks.
- Trial name
- NCT06637072
- Testing
- Efgartigimod PH20 SC
- Where
- 13 sites in United States
- Volunteers
- 23 people
- Sponsor
- argenx
Peritoneal Cancer, Ovarian Cancer
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
This research study was designed to determine the effectiveness of the drug, topotecan, given intravenously (into a vein) together with the drug gemcitabine in patients with recurrent platinum-sensitive ovarian, fallopian or…
- Conditions
- Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer
- Trial name
- NCT00061308
- Testing
- Topotecan, Gemcitabine
- Where
- 19 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- GlaxoSmithKline
Healthy Participants
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants
This study is being conducted to evaluate the pharmacokinetics, safety, and tolerability of INCA033989 following subcutaneous (SC) or intravenous administration (IV) n healthy adult participants.
- Trial name
- NCT07448155
- Testing
- INCA033989, Bioavailability enhancer
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Healthy
A Study in Healthy Men to Test How Different Doses of BI 3032950 Are Tolerated
The main objectives of this trial are to investigate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BI 3032950 in healthy male subjects following intravenous (Part A) or subcutaneous (Part B)…
- Trial name
- NCT05518708
- Testing
- BI 3032950
- Where
- Belgium
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Acute Myelogenous Leukemia
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
Primary objectives: To determine the maximum tolerated dose (MTD) of SAR103168 and to characterize the dose limiting toxicities (DLTs) in the proposed dose regimen To evaluate the pharmacokinetic (PK) profile of SAR103168…
- Trial name
- NCT00981240
- Testing
- SAR103168
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Sanofi
Graves Disease
NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
The purpose of this study is to evaluate how well MER511 is tolerated and what side effects may occur in adults who have Graves' disease.
- Trial name
- NCT07305818
- Testing
- MER511 (IV), MER511 (SC), MER511 (SC) for MAD
- Where
- 17 sites in United States, Spain
- Volunteers
- 100 people
- Sponsor
- Merida Biosciences
Thrombosis
Etude (Study) Phase I Enox - UnFractionated Heparin (UFH)
Primary objective: to characterize the pharmacokinetic and the pharmacodynamic profile after intravenous bolus injection of unfractionated heparin (UFH) after repeated sc 100 IU anti-Xa/kg (corresponding to 1 mg/kg) twice a day…
- Trial name
- NCT00622115
- Testing
- Enoxaparin
- Where
- France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Sanofi
Solid Tumors
AZD1152 in Patients With Advanced Solid Malignancies-Study 1
The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 2-hour infusion every week and every 2 weeks in patients with advanced solid malignancies.
- Trial name
- NCT00497731
- Testing
- AZD1152
- Where
- 2 sites in Netherlands
- Volunteers
- 70 people
- Sponsor
- AstraZeneca
Heart Failure
A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy Participants
Main Objective of this study is to compare the single intravenous (IV) infusion pharmacokinetics (PK) of BMS-986231 and its metabolites (BMT-284730, BMT-279554, and CAR-000463) following of up to 2 test formulations of BMS-986231…
- Trial name
- NCT03891108
- Testing
- BMS-986231 Formulation A, BMS-986231 Formulation B, BMS-986231 Formulation C
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Antithrombin Deficiency, Congenital
Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.
Patients with hereditary antithrombin (AT) deficiency are at increased risk of venous thrombosis and pulmonary embolism, particularly during certain high risk procedures.
- Trial name
- rhAT (NCT00056550)
- Testing
- Recombinant Human Antithrombin (rhAT)
- Where
- 11 sites in United States, France and 4 more
- Volunteers
- 14 people
- Sponsor
- rEVO Biologics
HER2+ Breast Cancer
Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer
This study evaluated the clinical benefits of intravenous administration of pyrotinib combined with trastuzumab subcutaneous preparation by comparing the efficacy and quality of life of intravenous administration in the treatment…
- Trial name
- NCT06537674
- Testing
- Trastuzumab intravenous drip/Trastuzumab Subcutaneous Injection
- Volunteers
- 100 people
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
Amyotrophic Lateral Sclerosis
ALS Phase II Study of NX210c
This study will investigate the efficacy, safety, tolerability and pharmacokinetics (PK) of multiple intravenous infusions of NX210c, at two dose levels, in patients with Amyotrophic lateral sclerosis (ALS).
- Trial name
- SEALS (NCT06365216)
- Testing
- NX210c
- Where
- 16 sites in France
- Volunteers
- 80 people
- Sponsor
- Axoltis Pharma
Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers
A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years
Researchers are looking for a better way to treat people who have acute venous and arterial thrombotic and thromboembolic events. These are severe medical problems due to blood clots forming in and blocking blood vessels.
- Trial name
- NCT06562985
- Testing
- BAY3018250 Dose 1, BAY3018250 Dose 2 infusion, BAY3018250 Dose 2 injection
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.